A retrospective analysis of the HALT-C trial demonstrated that the addition of the EGF SNP to clinical parameters (age, gender, smoking status, ALK-p level, and platelet count) could improve HCC risk stratification [164]. This evidence concerns the gene ALK and hepatocellular carcinoma.